What is Amgen's KRYSTEXXA — total revenues?

Amgen (AMGN) reported KRYSTEXXA — total revenues of $255M in Q1 2026.

How has Amgen's KRYSTEXXA — total revenues changed year-over-year?

Amgen's KRYSTEXXA — total revenues increased by 8.1% year-over-year, from $236M to $255M.

What does KRYSTEXXA — total revenues mean?

This metric represents the total gross sales generated from the specific therapeutic product line within the company's portfolio. It reflects the market demand, pricing power, and commercial adoption of this particular drug among the target patient population. Tracking this revenue stream is essential for evaluating the contribution of specialized pharmaceutical assets to the company's overall top-line growth and product lifecycle management.

Amgen AMGN KRYSTEXXA — Total revenues

Other product segments

Repatha

$3.02B—

Other products

$1.53B+3.6%

Prolia

$727M-33.8%

EVENITY

$562M+27.1%

TEPEZZA

$490M+28.6%

Otezla

$431M-1.4%

BLINCYTO

$415M+12.2%

Nplate

$412M+31.6%

XGEVA

$411M-27.4%

TEZSPIRE

$343M+20.4%

KYPROLIS

$330M+1.9%

ENBREL

$320M-37.3%

Aranesp

$311M-8.5%

Vectibix

$287M+7.5%

UPLIZNA

$262M+188%

IMDELLTRA/IMDYLLTRA

$258M+219%

Similar metrics at other companies

SUPNTrokendi XR — Total revenues

$9.48M-26.0%

BMYKrazati — Total Revenues

$55M+14.6%

SUPNAPOKYN — Total revenues

$7.73M-48.4%

SUPNOxtellar XR — Total revenues

$7.42M-27.2%

PBH

PBHDermatologicals — Total revenues

$30.49M+4.8%

SUPNQelbree — Total revenues

$77.84M+20.2%

Other financials

Income statement

See full

Revenue$8.6B+5.8%

Gross profit$5.9B+13.4%

Operating income$2.7B+126%

Net income$1.8B+5.1%

EPS (diluted)$3.34+4.4%

Balance sheet

See full

Cash & equivalents$559.0M+10.0%

Total debt$57.3B-0.1%

Total equity$9.2B+48.1%

Total assets$92.5B+3.5%

Cash flow

See full

Operating cash flow$2.2B+57.4%

CapEx$712.0M+73.2%

Free cash flow$1.5B+50.7%

Valuation

See full

Market cap$212.16B+30.0%

Enterprise value$268.92B+22.9%

P/E27.2×+2.5×

P/S5.7×+1.0×

Profitability

See full

Gross margin68.3%+5.3pp

Operating margin28.4%+6.6pp

Net margin21%+3.6pp

FCF margin23.1%-8.9pp

Returns & leverage

See full

Return on equity101.3%-4.4pp

Debt / equity6.2×-3.0×

Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's krystexxa — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's KRYSTEXXA — total revenues?: Amgen (AMGN) reported KRYSTEXXA — total revenues of $255M in Q1 2026.
How has Amgen's KRYSTEXXA — total revenues changed year-over-year?: Amgen's KRYSTEXXA — total revenues increased by 8.1% year-over-year, from $236M to $255M.
What does KRYSTEXXA — total revenues mean?: This metric represents the total gross sales generated from the specific therapeutic product line within the company's portfolio. It reflects the market demand, pricing power, and commercial adoption of this particular drug among the target patient population. Tracking this revenue stream is essential for evaluating the contribution of specialized pharmaceutical assets to the company's overall top-line growth and product lifecycle management.